Cellect Biotechnology (APOP) Stock: Skyrocketing On First Stem Cell Transplant


Cellect Biotechnology Ltd (NASDAQ: APOP)

Cellect Biotechnology is having an incredibly strong start to the trading session in the pre-market hours, and for good reason. Early this morning, the company announced its first stem cell transplant. As a result, excitement led to a frenzy among investors, pushing the stock up in a big way and prompting our partners at Trade Ideas to send us the alert. At the moment (8:53), APOP is trading at $7.74 per share after a gain of $1.45 per share (23.05%) thus far today.

APOP Announces First Patient Stem Cell Transplant

As mentioned above, Cellect Biotechnology is having a strong start to the day in the market after announcing its first stem cell transplant. According to the PR released by the company today, the first stem cell transplant procedure has been successfully completed using the company’s proprietary ApoGraft(TM) technology. This transplant is the first in the company’s Phase I/II clinical trial in the treatment of blood cancer. In a statement, Dr. Shai Yarkoni, CEO at APOP, had the following to offer:

After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions. It is a first good step on a road that we hope will lead to stem cell based regenerative medicine becoming a safe commodity treatment at every hospital in the world.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping an incredibly close eye on APOP. In particular, we’re interested in following the company’s work with regard to ApoGraft, as this could be a game changer in the oncology space. We’ll continue to follow the story and bring you the news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[Image Courtesy of Pixabay]

Check Out What The Trading Community Is Saying On StockTwits!


Please enter your comment!
Please enter your name here